Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 14INDUSTRY 11NIH 4NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Breast Neoplasms 5Wilms Tumor 4Prostatic Neoplasms 4Neoplasms 4Burkitt Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Plasmablastic Lymphoma 3Pancreatic Neoplasms 3Lymphoma 3Hematologic Neoplasms 3HIV Infections 3Ependymoma 3Colorectal Neoplasms 3Astrocytoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Melanoma 2Medulloblastoma 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Hodgkin Disease 2Head and Neck Neoplasms 2Glioblastoma 2

Interventions

carmustine, poliferprosan 20 drug combination 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Lenalidomide 1Etoposide 1Cytarabine 1Carmustine 1Bortezomib 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Lymphoma, Mantle-Cell × 30 days × Clear all
NCT01415752 2026-06-03

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
373 enrolled 14 charts
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT02797470 2026-05-18

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

AIDS Malignancy Consortium

Phase 1/2 Active not recruiting
11 enrolled 9 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, T-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡